KMS-11细胞系

KMS-11细胞KMS-11细胞系KMS-11人多发性骨髓瘤克隆细胞

Cell line name KMS-11

Synonyms KMS11; kms11; kms 11; Kawasaki Medical School-11

Accession CVCL_2989

Resource Identification Initiative To cite this cell line use: KMS-11 (RRID:CVCL_2989)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

Population: Japanese.

Characteristics: Produces IgG kappa.

Doubling time: 36 hours (PubMed=2519219); 70 hours (PubMed=25984343); 50 hours (Note=Lot 03062008), ~2 days (Note=Lot 10142009), ~31 hours (Note=Lot 10072016), ~39 hours (Note=Lot 10222021) (JCRB=JCRB1179).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: H3K27ac ChIP-seq epigenome analysis.

Omics: H3K4me1 ChIP-seq epigenome analysis.

Omics: H3K4me3 ChIP-seq epigenome analysis.

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.

Cell type: B-cell; CL=CL_0000236.

Sequence variations

Gene fusion; HGNC; HGNC:5722; IGKJ4 + HGNC; HGNC:5739; IGKV1-37; Name(s)=IGKV1-37-IGKJ4 (CelloPub=CLPUB00604).

Gene fusion; HGNC; HGNC:5723; IGKJ5 + HGNC; HGNC:5816; IGKV3-15; Name(s)=IGKV3-15-IGKJ5 (CelloPub=CLPUB00604).

Mutation; HGNC; HGNC:3690; FGFR3; Simple; p.Tyr373Cys (c.1118A>G); ClinVar=VCV000016342; Zygosity=Unspecified (PubMed=11157491; CelloPub=CLPUB00604).

Mutation; HGNC; HGNC:12033; TRAF3; Simple; p.Lys191Leufs*3; Zygosity=Homozygous (PubMed=17692805).

HLA typing Source: PubMed=25688540

Class I

HLA-A A*24

HLA-B B*51,54

HLA-C C*01,14

 

Source: PubMed=26589293

Class I

HLA-A A*24:02,24:02

HLA-B B*51:01,54:01

HLA-C C*01:02,14:02

Class II

HLA-DQ DQA1*03:02,05:01

DQB1*03:01,04:01

HLA-DR DRB1*04:05,14:03

Genome ancestry Source: PubMed=30894373

 

Origin % genome

African 4.44

Native American 0.01

East Asian, North 82.62

East Asian, South 10.11

South Asian 0

European, North 0

European, South 2.81

Disease Plasma cell myeloma (NCIt: C3242)

Multiple myeloma (ORDO: Orphanet_29073)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy Children:

CVCL_HE02 (KMS-11 WHSC1(+/-)) CVCL_HE03 (KMS-11 WHSC1(trans/-)) CVCL_VJ34 (KMS-11/BR)

CVCL_4V71 (KMS-11/BTZ) CVCL_IQ84 (KMS-11/Cfz) CVCL_D705 (KMS-11R)

Sex of cell Female

Age at sampling 67Y

Category Cancer cell line

STR profile Source(s): Cosmic-CLP=1659817; JCRB=JCRB1179; PubMed=25877200

 

Markers:

Amelogenin X

CSF1PO 13

D3S1358 15

D5S818 10,12

D7S820 11,12

D8S1179 13

D13S317 12

D16S539 9,13

D18S51 13,14

D21S11 28,30

FGA 22,24

Penta D 11,12

Penta E 15,16

TH01 6,9

TPOX 12

vWA 17,18

 

Publications

PubMed=2519219

Ohtsuki T., Yawata Y., Namba M.

Establishment and characterization of five human myeloma cell lines.

Hum. Cell 2:297-303(1989)

 

PubMed=2768132; DOI=10.1007/BF02623725

Namba M., Ohtsuki T., Mori M., Togawa A., Wada H., Sugihara T., Yawata Y., Kimoto T.

Establishment of five human myeloma cell lines.

In Vitro Cell. Dev. Biol. 25:723-729(1989)

 

PubMed=8943038; DOI=10.1073/pnas.93.24.13931; PMCID=PMC19472

Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L., Kuehl W.M.

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.

Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996)

 

PubMed=9787181; DOI=10.1182/blood.V92.9.3410

Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.

PTEN gene alterations in lymphoid neoplasms.

Blood 92:3410-3415(1998)

 

DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B

Otsuki T., Yamada O., Yata K., Nakazawa N., Taniwaki M., Sakaguchi H., Yawata Y., Ueki A.

Genetic and biological characterization of human myeloma cell lines: an overview of the lines established at Kawasaki Medical School.

Gene Funct. Dis. 1:48-56(2000)

 

DOI=10.1007/0-306-46877-8_4

Jernberg-Wiklund H., Nilsson K.

Multiple myeloma cell lines.

(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000)

 

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2

Drexler H.G., Matsuo Y.

Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.

Leuk. Res. 24:681-703(2000)

 

DOI=10.1016/B978-0-12-221970-2.50457-5

Drexler H.G.

The leukemia-lymphoma cell line factsbook.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)

 

PubMed=11157491; DOI=10.1182/blood.V97.3.729

Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., Kuehl W.M., Bergsagel P.L.

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.

Blood 97:729-736(2001)

 

PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2; PMCID=PMC1618545

Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S., Taniwaki M., Inazawa J.

Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.

Am. J. Pathol. 165:71-81(2004)

 

PubMed=15491288; DOI=10.1111/j.1365-2141.2004.05205.x

Otsuki T., Yata K., Takata-Tomokuni A., Hyodoh F., Miura Y., Sakaguchi H., Hatayama T., Hatada S., Tsujioka T., Sato Y., Murakami H., Sadahira Y., Sugihara T.

Expression of protein gene product 9.5 (PGP9.5)/ubiquitin-C-terminal hydrolase 1 (UCHL-1) in human myeloma cells.

Br. J. Haematol. 127:292-298(2004)

 

PubMed=16956823